Recent advances in clinical application and laboratory testing for Emicizumab

VernacularTitle:艾美赛珠单抗的临床应用与实验室检测新进展
Author: Dong PENG ¹ ; Ying WANG ; Xiaoying FU
Author Information

1. 深圳市儿童医院医学检验科，深圳　518038
Publication Type:Journal Article
Keywords: Antibodies, monoclonal; Hemophilia A; Clinical laboratory techniques; Emicizumab
From: Chinese Journal of Laboratory Medicine 2025;48(9):1254-1260
CountryChina
Language:Chinese
Abstract: Emicizumab (EMI) is a non-factor treatment drug, as a revolutionary bispecific antibody, it has shown significant efficacy and safety in the treatment of hemophilia A (HA). However, EMI affects the activated partial thromboplastin time (APTT) test, thus the results of traditional APTT testing and one-stage coagulation factor determination based on APTT cannot reflect the true hemostatic status of patients treated with EMI, presenting a unique challenge to the laboratory assessment of hemostasis in patients with HA.This review aims to explore the clinical application of EMI in the treatment of HA, as well as the new advancements in laboratory testing that have emerged alongside its use.